

WISDOM 2021

20th – 22nd August 2021



WISDOM 2021 FOGSI - AOFOG - SAFOG

Virtual Conference

Registration / Viewer's Link: https://bit.ly/Wisdom_2021



Dr S. Shantha Kumari
President, FOGSI



Dr Kazunori Ochiai
President, AOFOG



Dr Rohana Haththotuwa
President, SAFOG



Dr Madhuri Patel
Secretary General, FOGSI



Dr Jaydeep Tank
Deputy Secy General, AOFOG
Convenor



Dr Yousaf Latif Khan
Secretary, SAFOG



Dr Krishnendu Gupta
FOGSI Representative, AOFOG
Organising Chair



Dr Bhaskar Pal
FOGSI Representative, SAFOG
Organising Chair



Dr Basab Mukherjee
Vice President, FOGSI
Organising Secretary

Theme :

Blending **Evidence** and
Experience into **Practice**



WISDOM 2021

FOGSI-AOFOG-SAFOG Virtual Conference

Theme : Blending Evidence and Experience into Practice

Date: 20th to 22nd August 2021

Registration / Viewer's Link: https://bit.ly/Wisdom_2021

WORKSHOPS

20th August 2021

WORKSHOP 3.00–6.00 PM	REPRODUCTIVE ENDOCRINOLOGY	ADOLESCENT HEALTH (Partner : SRH Committee, AOFOG)	FETAL MEDICINE (Partner : Fetal Medicine Committee, SAFOG)
CONVENORS	<i>Dr Ameya Purandare Dr Rakhi Singh</i>	<i>Dr Shyjus P Dr Girish Mane</i>	<i>Dr Archana Baser Dr Neharika Malhotra</i>
3.00–4.00 PM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	Chairs <i>Dr Anju Turior Dr Nabanita Deka Dr Sushanta Das</i> Insulin Sensitizers in PCOS <i>Dr Dibyendu Banerjee</i> Assessment of Primary Amenorrhoea <i>Dr Suvarna Khadilkar</i> Management of Hirsutism <i>Dr Ashok Kumar</i>	Chairs <i>Dr Bharati More Dr Rajal Thakkar Dr Vijayalakshmi Seshadri</i> Life Skill Education for Adolescents <i>Dr Vaidehi Marathe</i> Adolescent Nutrition and its Impact on Gynaecological Development <i>Dr Angela Aguilar (Philippines)</i> Adolescent Contraception <i>Dr Unnop Jaisamrarn (Thailand)</i>	Chairs <i>Dr Anu Vij Dr Indira Palo Dr Kaushik Das</i> Screening for Downs Syndrome <i>Dr Gayatri V</i> The 11-14 wk Scan - Beyond Aneuploidy <i>Dr K Aparna Sharma</i> Genetics for Obstetricians <i>Dr Mandakini Pradhan</i>
4.00–5.00 PM	SYMPOSIUM	SYMPOSIUM	KEYNOTE LECTURES
	Chairs <i>Dr Jyothi Bunglowala Dr Rajasi Sengupta Dr Udayan Sarkar</i> Hyperprolactinemia <i>Dr Muralidhar V Pai</i> Current Status of MHT <i>Dr Raymond Li (Hong Kong)</i> Long Term Consequences of PCOS <i>Dr Jayam Kannan</i>	Chairs <i>Dr Nivedita Datta Dr Praneshwari Devi Dr Supriya Arwari</i> Adolescent PCOS <i>Dr Charmila Aayavoo</i> Adolescent Friendly Services <i>Dr Archana Verma</i> Puberty Menorrhagia <i>Dr Jayita Chakrabarti</i>	Chairs <i>Dr Kusagradhi Ghosh Dr Priyanka Kamble Dr Raju Sahetya</i> Diagnosis and Management of Late Onset FGR <i>Dr UDP Ratnasiri (Sri Lanka)</i> Imaging the Placenta <i>Dr P K Shah</i> Managing Rh Isoimmunisation <i>Dr Vatsala Dadhwal</i>
5.00–6.00 PM	PANEL	PANEL	PANEL
	Recurrent Miscarriage Moderators <i>Dr Ameya Purandare Dr Rakhi Singh</i> Panelists <i>Dr Anshu Raina Dr Deepa Mukandan Dr Meenu Agarwal Dr Pratik Tambe Dr Radha T Dr Ranjana Khanna</i>	Case Discussions in Adolescent Health Moderators <i>Dr Girish Mane Dr Shyjus P</i> Panelists <i>Dr Anita Sabharwal Dr Oby Nagar Dr Sampathkumari Dr Supriya Jaiswal Dr Vinita Singh Dr Yashodhara Pradeep</i>	Challenging Cases In Fetal Medicine Moderators <i>Dr Archana Baser Dr Selvapriya S</i> Panelists <i>Dr Jyotsna Rani Panigrahi Dr Kanchan Mukherjee Dr Mukta Agarwal Dr Neharika Malhotra Dr Poonam Goyal Dr Pragya Mishra</i>
WORKSHOP 6.00–9.00 PM	ART	SAFE ABORTION	ENDOSCOPY
CONVENORS	<i>Dr Kundan Ingle Dr Rohan Palshetkar</i>	<i>Dr Richa Sharma Dr Shehla Jamal</i>	<i>Dr Aswath Kumar Dr Mala Raj</i>
6.00–7.00 PM	SYMPOSIUM	SYMPOSIUM	KEYNOTE LECTURES
	Chairs <i>Dr Aditya Khurd Dr Chaitanya Shembekar Dr Manoj Chellani</i> Role of LH in COS <i>Dr Sonia Malik</i> Micronutrients in Sub fertility <i>Dr Padmaja (Vijaywada)</i> Assessment of Male Infertility <i>Dr N Sanjeeva Reddy</i>	Chairs <i>Dr Amrit Dhillon Dr Pranay Phukan</i> Decoding the MTP Act <i>Dr Hitesh Bhatt</i> Second Trimester MTP <i>Dr Shehla Jamal</i> Surgical TOP <i>Dr Richa Sharma</i>	Chairs <i>Dr Kawita Bapat Dr Rajendra Sankpal Dr Sujata Kar</i> Gynaecological Endoscopy Treatment During the Pandemic: Important Considerations <i>Dr Tsukasa Baba (Japan)</i> Laparoscopy for Managing CS Complications <i>Dr Alka Kriplani</i> Controversies in Power Morcellation <i>Dr Prakash Trivedi</i>
7.00–8.00 PM	SYMPOSIUM	KEYNOTE LECTURES	VIDEO SESSION
	Chairs <i>Dr Alok Basu Dr Mousumi Das Ghosh Dr Rajiv Vyas</i> Understanding AMH <i>Dr Pratap Kumar</i> Myomectomy in Infertility – Which & How? <i>Dr Sunita Tandulwadkar</i> Tubal Factor Infertility <i>Dr Fessy Louis</i>	Chairs <i>Dr Bipin Pandit Dr Jamuna K Dr Roza Olyai</i> Abortion in Adolescents <i>Dr Nozer Sheriar</i> Abortion Services in the COVID Era <i>Dr Jaydeep Tank</i> Medication Abortion – What's new? <i>Dr Basab Mukherjee</i>	Chairs <i>Dr Ashvin Vachani Dr Jagjit Singh Dr Neelam Mishra</i> Hysteroscopic Adhesiolysis <i>Dr S Krishnakumar</i> Laparoscopic Myomectomy for Unusual Fibroids <i>Dr Mala Raj</i> Electrosurgery in Laparoscopy <i>Dr Laila Arjumand Bano (Bangladesh)</i>
8.00–9.00 PM	PANEL	PANEL	PANEL
	Case Scenarios in ART Moderators <i>Dr Kundan Ingale Dr Ashish Kale</i> Panelists <i>Dr Hima Deepti Dr Jyoti Malik Dr Rohan Palshetkar Dr Seema Pandey Dr Shivani Sachdev Gaur Dr Varsha Baste</i>	Difficult Case Scenarios at MTP Moderators <i>Dr Parikshit Tank Dr Kiran Kurtokoti</i> Panelists <i>Dr Bharti Maheshwari Dr Dipak Bhagde Dr Geetendra Sharma Dr Narasimha Reddy Dr Ritu Joshi Dr Shyamal Sett</i>	Complications in Laparoscopy Surgery Moderators <i>Dr Manjula Anagani Dr Aswath Kumar</i> Panelists <i>Dr Anupama Bahadur Dr Arti Luthra Dr Bijoy Nayak Dr Binal Shah Dr Kalyan Barmade Dr Sujal Munshi Dr Tanvi Singh</i>



WISDOM 2021

FOGSI-AOFOG-SAFOG Virtual Conference

Theme : Blending Evidence and Experience into Practice

Date: 20th to 22nd August 2021

Registration / Viewer's Link: https://bit.ly/Wisdom_2021

SCIENTIFIC SESSION

21st August 2021

2.00–2.45 PM	INAUGURATION		
	WELCOME ADDRESS: <i>Dr Krishnendu Gupta</i> President Secretary General VOTE OF THANKS: <i>Dr Bhaskar Pal</i>		
2.45–4.00 PM	PRESIDENTIAL SESSION		
	Chairs <i>Dr Jaydeep Tank</i> <i>Dr Mandakini Megh</i> <i>Dr Rashid Latif Khan</i> Violence Against Women <i>Dr S Shantha Kumari</i> Ovarian Cancer Surgery: Lessons from COVID-19 Pandemic <i>Dr Kazunori Ochiai (Japan)</i> Preventing the Primary Caesarean Section <i>Dr Rohana Haththotuwa (Sri Lanka)</i>		
Hall Co ordinators	<i>Dr Dr Indrani Roy</i> <i>Dr Anshu Raina</i> <i>Dr Priyankur Roy</i> <i>Dr Seetha Ramamurthy</i>	<i>Dr Anantha Lakshmi</i> <i>Dr Manjula Rao</i>	<i>Dr Subash Mallya</i> <i>Dr Siddhesh Aiyar</i> <i>Dr Riddhi Desai</i>
4.00–5.00 PM	KEYNOTE LECTURES	PANEL	SYMPOSIUM
	Chairs <i>Dr Archana Verma</i> <i>Dr Atul Munshi</i> <i>Dr Gokul Das</i> Updates on Diagnosis & Management of Endometriosis <i>Dr Farrukh Zaman (Pakistan)</i> SDG 2030: Realities for SAFOG Region <i>Dr Rubina Sohail (Pakistan)</i> Emerging Public Health Issues in Maternal Health <i>Dr Sudha Sharma (Nepal)</i>	Hyperglycaemia in Pregnancy Moderators <i>Dr Hema Divakar</i> <i>Dr Priti Kumar</i> Panelists <i>Dr Alka Pandey</i> <i>Dr Hemant Deshpande</i> <i>Dr Manjula Rao</i> <i>Dr Uma Mikkilineni</i> <i>Dr Uma Ram</i> <i>Dr Vaishali Chavan</i>	Chairs <i>Dr Alpina Chetty</i> <i>Dr Amrita Sarkar Jaipuria</i> <i>Dr Manikya Rao</i> Setting up a Vulval Clinic <i>Dr Lila Vyas</i> Vulvodynia <i>Dr Sameena Choudhury (Bangladesh)</i> VIN <i>Dr Ashwini Bhalerao Gandhi</i> Managing Recurrent Vaginitis <i>Dr Ramprasad Dey</i>
5.00–6.00 PM	KEYNOTE LECTURES	PANEL	SYMPOSIUM
	Chairs <i>Dr Fessy Louis</i> <i>Dr Kiranmai Devineni</i> <i>Dr Usha Sharma</i> Iron Therapy in Pregnancy <i>Dr P C Mahapatra</i> Ovulation Induction in PCOS <i>Dr Nandita Palshetkar</i> Cervical Ripening – New Trends <i>Dr Jayanthi Reddy</i>	Complications of Hysterectomy Moderators <i>Dr Shyam Desai</i> <i>Dr Sarita Bhalerao</i> Panelists <i>Dr Anantha Lakshmi</i> <i>Dr Anita Singh</i> <i>Dr Arun Madhab Baruah</i> <i>Dr Hara Pattanaik</i> <i>Dr Irrinki Lakshmi</i> <i>Dr Rajendra Singh Pardeshi</i> <i>Dr Ratna Talukdar</i>	Chairs <i>Dr Luna Pant</i> <i>Dr Saktirupa Chakraborty</i> Obstetric Cholestasis <i>Dr Meena Samant</i> Prediction of Preterm Labour <i>Dr Seetha Ramamurthy</i> Management of PPROM <i>Dr Komal Chavan</i> Progesterone in Preterm Labor <i>Dr Girija Wagh</i>
6.00–7.00 PM	KEYNOTE LECTURES	PANEL	SYMPOSIUM
	Chairs <i>Dr Basab Mukherjee</i> <i>Dr Meera Agnihotri</i> <i>Dr Sharda Jain</i> Effects of COVID 19 in Pregnancy <i>Dr Alpesh Gandhi</i> There is Only Now (Time Management for Doctors) <i>Dr Jaideep Malhotra</i> Improving Fertility Outcomes in Female Genital Tuberculosis <i>Dr Rishma Pai</i>	Gynae Oncology Moderators <i>Dr Neerja Bhatla</i> <i>Dr Niranjana Chavan</i> Panelists <i>Dr Aliya Begum (Pakistan)</i> <i>Dr Bhagyalakshmi Nayak</i> <i>Dr Kiran Pandey</i> <i>Dr M M Samsuzzoha</i> <i>Dr Priya Ganesh Kumar</i> <i>Dr Sarikapan Wilailak (Thailand)</i> <i>Dr Tushar Kar</i>	Chairs <i>Dr J P Mour</i> <i>Dr Kusumlata Meena</i> <i>Dr Nirmala Pipara</i> Managing Miscarriage <i>Dr Nilesh Balkawade</i> Luteal Phase Defect <i>Dr Ritu Khanna</i> Hyperemesis <i>Dr Tulika Jha</i> Non-tubal Ectopic Pregnancy <i>Dr Subhas Mallya</i>
7.00–8.00 PM	SYMPOSIUM	Panel	SYMPOSIUM
	Obstetrics Chairs <i>Dr Alakananda Das</i> <i>Dr Hafizur Rahman</i> <i>Dr Sajal Datta</i> Managing ART Pregnancies <i>Dr Laxmi Shrikhande</i> Vaccination in Pregnancy <i>Dr Anahita Chauhan</i> COVID Vaccine in Pregnancy <i>Dr Sujata Dalvi</i> Shoulder Dystocia <i>Dr Aruna Suman</i>	Received Legal Notice: What Next? Moderators <i>Dr Bipin Pandit</i> <i>Dr Alka Mukherjee</i> Panelists <i>Dr Ajay Mane</i> <i>Dr Alka Kuthe</i> <i>Dr Dilip Walke</i> <i>Dr Manish Machave</i> <i>Dr Mousumi De Banerjee</i> <i>Dr Rahul Wani</i>	Mixed Bag Chairs <i>Dr Alka Sethi</i> <i>Dr Ayona Borthakur</i> <i>Dr Suranjan Chakraborty</i> Female Sexual Dysfunction <i>Dr Niraj Jadav</i> Gynaecologist's Role in Early Detection of Breast Cancer <i>Dr Sneha Bhuiyar</i> Preventing MTCT in HIV <i>Dr Anju Soni</i> Outpatient Hysteroscopy <i>Dr Parul Kotdawala</i>
8.00–9.00 PM	PLENARY		
	Chairs <i>Dr Krishnendu Gupta</i> <i>Dr Suchitra Pandit</i> Implementation of EBM into Reproductive Health Practice: A Role of Research Synthesis <i>Dr Pisake Lumbiganon</i> Still Birth in SAFOG Region <i>Dr Ferdousi Begum</i>		



WISDOM 2021

FOGSI-AOFOG-SAF OG Virtual Conference

Theme : Blending Evidence and Experience into Practice

Date: 20th to 22nd August 2021

Registration / Viewer's Link: https://bit.ly/Wisdom_2021

SCIENTIFIC SESSION

22nd August 2021

9.45–11.00 AM	PLENARY		
	<p>Chairs <i>Dr Kiyoko Kato (Japan)</i> <i>Dr Tsung-Hsien Su (Taiwan)</i> <i>Dr Usha Saraiya</i></p> <p>HPV Vaccination – are we really doing enough? <i>Dr Krishnendu Gupta</i></p> <p>Fertility Preservation: An Overview <i>Dr Hrishikesh Pai</i></p> <p>Ectopic Pregnancy: Reducing Mortality & Morbidity <i>Dr Bhaskar Pal</i></p>		
Hall Co ordinators	<i>Dr Tulika Jha</i> <i>Dr Shruti Thar</i> <i>Dr Hima Deepti</i> <i>Dr Laxmi Chirumamilla</i>	<i>Dr Mariam Khanam</i> <i>Dr Poushali Sanyal</i>	<i>Dr Tanvi Singh</i> <i>Dr Priyanka Pipara</i> <i>Dr Runa Acharya</i>
11.00–12.00 PM	KEYNOTE LECTURES	PANEL	SYMPOSIUM
	<p>Chairs <i>Dr Chandravati</i> <i>Dr Jayant Rath</i> <i>Dr P Balamba</i></p> <p>Fertility Enhancing Endoscopic Surgery <i>Dr Yousuf Latif Khan (Pakistan)</i></p> <p>COVID 19: a silver lining? <i>Dr Ravi Chandran (Malaysia)</i></p> <p>Violence Against Women & Our Response <i>Dr Alokendu Chatterjee</i></p>	<p>Endometriosis</p> <p>Moderators <i>Dr Asha Rao</i> <i>Dr Ramani Devi</i></p> <p>Panelists <i>Dr Anita Rajorhia</i> <i>Dr Charu Bapaye</i> <i>Dr Garuda Lakshmi</i> <i>Dr Priyankur Roy</i> <i>Dr Sandhya Saharan</i> <i>Dr Varsha Lahade</i> <i>Dr Vidhu Modgil</i></p>	<p>Chairs <i>Dr Abha Rani Sinha</i> <i>Dr Abinash Chandra Roy</i> <i>Dr Vaishali Korde Nayak</i></p> <p>Carbetocin in PPH Prevention <i>Dr Yashitha Poojari</i></p> <p>Medical Management of PPH <i>Dr Vidya Thobbi</i></p> <p>Managing PPH at CS <i>Dr Mahesh Gupta</i></p> <p>Obstetric Hysterectomy <i>Dr Pratima Mittal</i></p>
12.00–1.00 PM	KEYNOTE LECTURES	PANEL	SYMPOSIUM
	<p>Chairs <i>Dr Abha Singh (Raipur)</i> <i>Dr P K Sekaran</i></p> <p>Obesity in Obstetrics: Problems of Plenty <i>Dr Madhuri Patel</i></p> <p>The First 1000 Days of Life and NCDs <i>Dr Sanjay Gupte</i></p> <p>Planning Delivery in FGR <i>Dr Uday Thanawala</i></p>	<p>Obstetric Sepsis</p> <p>Moderators <i>Dr Ashis Mukhopadhyay</i> <i>Dr Geeta Balsarkar</i></p> <p>Panelists <i>Dr Arun Nayak</i> <i>Dr Biswajyoti Guha</i> <i>Dr Gunnam Sujayarsi</i> <i>Dr Indranil Dutta</i> <i>Dr Mitra Saxena</i> <i>Dr Surekha Tayade</i> <i>Dr Uma Pandey</i></p>	<p>Urogynaecology</p> <p>Chairs <i>Dr Amit Basu</i> <i>Dr Mangesh Narwadkar</i> <i>Dr Mou-Jong Sun</i></p> <p>Assessment of Urinary Incontinence <i>Dr Nita Thakre</i></p> <p>Management of Overactive Bladder <i>Dr J B Sharma</i></p> <p>Management of SUI <i>Dr Subhas Biswas</i></p> <p>Managing Vault Prolapse <i>Dr Vineet Mishra</i></p>
1.00–2.00 PM	SYMPOSIUM	Panel	SYMPOSIUM
	<p>Obstetrics</p> <p>Chairs <i>Dr Padmini Prasad</i> <i>Dr Suman Sinha</i> <i>Dr Susmita Chattopadhyay</i></p> <p>Robson's Classification for Optimizing CS <i>Dr Lubna Hassan (Pakistan)</i></p> <p>USG in PAS <i>Dr Chinmayee Ratha</i></p> <p>Reviving Instrumental Delivery <i>Dr Krishnakumari</i></p> <p>Difficult Deliveries at CS <i>Dr T. Vindhya</i></p>	<p>Midlife Management</p> <p>Moderators: <i>Dr Narendra Malhotra</i> <i>Dr Kawita Bapat</i></p> <p>Panelists: <i>Dr Archana Dwivedi</i> <i>Dr Maninder Ahuja</i> <i>Dr M G Hiremath</i> <i>Dr Pratibha Singh</i> <i>Dr Rajendra Nagarkatti</i> <i>Dr Tarini Taneja</i></p>	<p>Mixed Bag</p> <p>Chairs <i>Dr Arup Kumar Majhi</i> <i>Dr Manoranjan Mahapatra</i> <i>Dr Sujata Bhatt</i></p> <p>Advances in Gynecological Imaging <i>Dr Nelinda Catherine Pangilinan (Philippines)</i></p> <p>Screening for Ovarian Ca – Updated Recommendations <i>Dr Sadhana Gupta</i></p> <p>Surgical Management of Mullerian Anomalies <i>Dr Hiralal Konar</i></p> <p>Thyroid Disorders in Pregnancy <i>Dr Chaitali Datta Roy</i></p>
2.00–3.00 PM	SYMPOSIUM	PANEL	SYMPOSIUM
	<p>Contraception</p> <p>Chairs <i>Dr Asha Jain</i> <i>Dr Janmejaya Mahapatra</i> <i>Dr Sujata Sharma</i></p> <p>LARC <i>Dr Sebanti Goswami</i></p> <p>Hormonal Contraception - Non contraceptive benefits <i>Dr Ragini Agrawal</i></p> <p>Post abortal Contraception <i>Dr Shobha Gudi</i></p> <p>Contraception in Medical Diseases <i>Dr Achla Batra</i></p>	<p>HDP</p> <p>Moderators: <i>Dr Parag Biniwale</i> <i>Dr Atul Ganatra</i></p> <p>Panelists: <i>Dr Archana Singh</i> <i>Dr Indrani Roy</i> <i>Dr Madhu Bindu</i> <i>Dr Mala Shrivastava</i> <i>Dr Mritunjay Bellad</i> <i>Dr N Palaniappan</i> <i>Dr Sreelakshmi</i></p>	<p>Mixed Bag</p> <p>Chairs <i>Dr Rekha Jha</i> <i>Dr Sukanta Misra</i></p> <p>LMIC: Is Delivery in High Quality Obstetric Facilities Geographically Feasible? <i>Dr Archana Amatya (Nepal)</i></p> <p>Taking the Use of Magsulf to the community in Management of Eclampsia <i>Dr Farhana Dewan (Bangladesh)</i></p> <p>Maternal Health Situation in Bhutan <i>Dr Phurb Dorjee (Bhutan)</i></p> <p>Maternal Mortality in Sri Lanka: New Strategies <i>Dr Sanath Lanerolle (Sri Lanka)</i></p>
3.00–4.00 PM	PLENARY		
	<p>Chairs <i>Dr Shanthakumari S</i> <i>Dr T A Choudhury</i></p> <p>"Knowledge Comes and Wisdom lingers- Challenges to Evidenced Based Medicine" <i>Dr S Arulkumaran</i></p> <p>TBC <i>Dr CN Purandare</i></p>		
4.00–4.30 PM	VALEDICTORY		

Make **HER** Win in Every Phase of Life

In TA, RPL & LPS

Dydrofem

Dydrogesterone Tablets IP 10 mg

— Indigenous Dydrogesterone —

In IDA* during Pregnancy & Lactation

Orofer[®] XT
Tablets

Ferrous Ascorbate equivalent to 100 mg elemental iron + Folic Acid 1.5 mg Tablets

Hb rise... simply unmatched

In Iron Deficiency Anemia,

Orofer[®] FCM 1K
Ferric Carboxymaltose Injection equivalent to elemental iron 1000 mg/20 ml

Assured Hb Rise... Conveniently

In Dysmenorrhea Associated with Menorrhagia

Pause[®]-MF
Tranexamic Acid 500 mg + Mefenamic Acid 250 mg Tablet

Synergy To Control Blood Loss with Pain

Emcure[®]
SUCCESS THROUGH INNOVATION



The Leader in Gynecology

FOR LPS IN ART

TRUST 30[™] TO DELIVER

IF IT'S **ORALLY** EFFECTIVE, IT'S[†]

Duphaston[®]

Dydrogesterone Tablets IP 10 mg

BACKED BY **EVIDENCE**DOSAGE FOR
LPS IN ART**30 mg**

per day

starting at

the day of

oocyte retrieval

and continuing

for 10 weeks.*



Pictures are for representation purpose only and not of actual patients.

LPS: Luteal phase support. **ART:** Assisted reproductive technology.
† Schindler AE. Progestational effects of dydrogesterone *in vitro*, *in vivo* and on human endometrium. *Maturitas*. 2009;65 (1):S3-S11. ‡ Pubmed. Search results for Dydrogesterone on Pubmed.gov. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/?term=Dydrogesterone>. Last accessed on 24.01.2020.
*Prescribing information of Duphaston[®]. Version: 6.0, dated 27th June, 2018. II 30 refers to dosage of Duphaston in LPS as a part of ART treatment: 30 mg per day starting at day of oocyte retrieval and continuing upto 10 weeks (as per Duphaston PI). # Data on file.

ABBREVIATED PRESCRIBING INFORMATION:
Dydrogesterone Tablets IP Duphaston[®]. LABEL CLAIM: Each film coated tablet contains: Dydrogesterone IP 10 mg. Excipients q.s. Colour: Titanium dioxide IP. **INDICATION:** Progesterone deficiencies: Treatment of dysmenorrhoea; Treatment of endometriosis; Treatment of secondary amenorrhoea; Treatment of irregular cycles; Treatment of dysfunctional uterine bleeding; Treatment of premenstrual syndrome; Treatment of threatened miscarriage; Treatment of habitual miscarriage; Treatment of infertility due to luteal insufficiency; Luteal support as part of an Assisted Reproductive Technology (ART) treatment and Hormone replacement therapy. **DOSAGE AND ADMINISTRATION:** Dysmenorrhoea: 10 or 20 mg dydrogesterone per day from day 5 to day 25 of the menstrual cycle. Endometriosis: 10 to 30 mg dydrogesterone per day from day 5 to day 25 of the cycle or continuously. Dysfunctional uterine bleeding: When treatment is started to arrest a bleeding episode, 20 or 30 mg dydrogesterone per day is to be given for up to 10 days.

Secondary amenorrhoea: 10 or 20 mg dydrogesterone per day, to be given daily for 14 days during the second half of the theoretical menstrual cycle to produce an optimum secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Pre-menstrual syndrome: 10 mg dydrogesterone twice daily starting with the second half of the menstrual cycle until the first day of the next cycle. The starting day and the number of treatment days will depend on the individual cycle length. Irregular cycles: 10 or 20 mg dydrogesterone per day starting with the second half of the menstrual cycle until the first day of the next cycle. The starting day and the number of treatment days will depend on the individual cycle length. Threatened miscarriage: An initial dose of up to 40 mg dydrogesterone may be given followed by 20 or 30mg per day until symptoms remit. Habitual miscarriage: 10 mg dydrogesterone twice daily until the twentieth week of pregnancy. Infertility due to luteal insufficiency: 10 or 20 mg dydrogesterone daily starting with the second half of the menstrual cycle until the first day of the next cycle. Treatment should be maintained for at least three consecutive cycles. Luteal support as part of an Assisted Reproductive Technology (ART) treatment: 10 mg Dydrogesterone three times a day (30 mg daily) starting at the day of oocyte retrieval and continuing for 10 weeks if pregnancy is confirmed. Hormone replacement therapy: Continuous sequential therapy: An estrogen is dosed continuously and one tablet of 10mg dydrogesterone is added for the last 14 days of every 28-day cycle, in a sequential manner. Cyclic therapy: When an estrogen is dosed cyclically with a treatment-free interval, usually 21 days on and 7 days off. One tablet of 10 mg dydrogesterone is added for the last 12-14 days of estrogen therapy. **CONTRAINDICATIONS:** Known hypersensitivity to the active substance or to any of the

excipients. Known or suspected progestogen dependent neoplasms (e.g. meningioma). Undiagnosed vaginal bleeding. Treatment for luteal support as part of an Assisted Reproductive Technology (ART) treatment should be discontinued upon diagnosis of abortion /miscarriage. Contraindications for the use of estrogens when used in combination with dydrogesterone. **WARNINGS & PRECAUTIONS:** Before initiating dydrogesterone treatment for abnormal bleeding the etiology for the bleeding should be clarified. Breakthrough bleeding and spotting may occur during the first months of treatment. If breakthrough bleeding or spotting appears after some time on therapy, or continues after treatment has been discontinued, the reason should be investigated, which may include endometrial biopsy to exclude endometrial malignancy. If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised. It should be taken into account that these conditions may recur or be aggravated during treatment with dydrogesterone and ceasing the treatment should be considered: Porphyria, Depression and Abnormal liver function values caused by acute or chronic liver disease. **PREGNANCY & LACTATION:** It is estimated that more than 10 million pregnancies have been exposed to dydrogesterone. So far there were no indications of a harmful effect of dydrogesterone use during pregnancy. Dydrogesterone can be used during pregnancy if clearly indicated. Breastfeeding: No data exist on excretion of dydrogesterone in mother's milk. Experience with other progestogens indicate that progestogens and the metabolites pass to mother's milk in small quantities. Whether there is a risk to the child is not known. Therefore, dydrogesterone should not be used during the lactation period. Fertility: There

is no evidence that dydrogesterone decreases fertility at therapeutic dose. **ADVERSE REACTIONS:** The most commonly reported adverse drug reactions of patients treated with dydrogesterone in clinical trials of indications without estrogen treatment are migraines/headache, nausea, menstrual disorders and breast pain/tenderness. Undesirable effects in adolescent population: Based on spontaneous reports and limited clinical trial data, the adverse reaction profile in adolescents is expected to be similar to that seen in adults. Undesirable effects that are associated with an estrogen-progestogen treatment (see also 'Warnings and Precautions' and the product information of the estrogen preparation): Breast cancer, endometrial hyperplasia, endometrial carcinoma, ovarian cancer; Venous thromboembolism; Myocardial infarction, coronary artery disease, ischemic stroke. Issued on: Date (20/11/2019). Source: Prepared based on full prescribing information (version 8) dated 20/Nov/2019. * Registered Trademark of the Abbott Products Operations AG.

For full prescribing information, please contact: Abbott India Limited, Floor 16, Godrej BKC, Plot C-68, 'G' Block, Bandra-Kurla Complex, Near MCA Club, Bandra East, Mumbai-400 051. www.abbott.co.in
Copyright 2020 Abbott. All rights reserved.

THE POWER TO DO MORE, NOW AT YOUR FINGERTIPS



Introducing the **Bare Your Pain app**, to help endometriosis patients adhere to treatment better and also help you make informed decisions.



PLEASE SCAN
THE QR CODE
TO DOWNLOAD
THE APP



Visanne®
Dienogest 2mg 

With best compliments from

Susten Cap

Natural Micronised Progesterone 100 mg/ 200 mg/
300 mg/ 400 mg SLDS Capsule



Letroz

Letrozole 2.5 mg tab



Susten SR

Sustained Release Natural Micronised Progesterone 400 mg/300 mg/200 mg Tablets

